KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study

Karen-Lise Garm Spindler, René dePont Christensen, Rikke Fredslund Andersen, Niels Pallisgaard, Anders Johnsson, Anders Jakobsen

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

OriginalsprogEngelsk
Publikationsdato2012
StatusUdgivet - 2012
BegivenhedThe 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Dublin, Irland
Varighed: 6. nov. 20129. nov. 2012

Konference

KonferenceThe 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LandIrland
ByDublin
Periode06/11/201209/11/2012

Citer dette

@conference{031d3abb0ff141d796f2a2598bd8bafc,
title = "KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study",
author = "Spindler, {Karen-Lise Garm} and Christensen, {Ren{\'e} dePont} and {Fredslund Andersen}, Rikke and Niels Pallisgaard and Anders Johnsson and Anders Jakobsen",
year = "2012",
language = "English",
note = "null ; Conference date: 06-11-2012 Through 09-11-2012",

}

KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study. / Spindler, Karen-Lise Garm; Christensen, René dePont; Fredslund Andersen, Rikke; Pallisgaard, Niels; Johnsson, Anders; Jakobsen, Anders.

2012. Poster session præsenteret på The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Irland.

Publikation: Konferencebidrag uden forlag/tidsskriftPosterForskningpeer review

TY - CONF

T1 - KRAS, BRAF, and PIK3CA mutations as predictors of outcome of maintenance therapy with bevacizumab with or without erlotinib after first line combination chemotherapy for mCRC. Results of the phase III Nordic ACT trial NCT00598156 translational study

AU - Spindler, Karen-Lise Garm

AU - Christensen, René dePont

AU - Fredslund Andersen, Rikke

AU - Pallisgaard, Niels

AU - Johnsson, Anders

AU - Jakobsen, Anders

PY - 2012

Y1 - 2012

M3 - Poster

ER -